Satellos Bioscience Inc. Common Stock

Satellos Bioscience, Inc. is a regenerative medicine firm dedicated to creating novel therapeutic solutions. The company employs its proprietary MyoReGenX™ technology platform, which enables the identification of stem cell regeneration deficits within various muscle diseases and subsequently facilitates the development of targeted treatments. Frank Gleeson and Michael Rudnicki established the company on July 27, 2012, and its corporate headquarters are located in Toronto, Canada.